FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.734,16 +3.652,02 (+6,63%)
MannKind Corporation (MNKD)
Dopo ore:
| Chiusura precedente | 4,3800 |
| Aperto | 4,4500 |
| Denaro | 4,3800 x 900 |
| Lettera | 4,4100 x 900 |
| Min-Max giorno | 4,3400 - 4,4900 |
| Intervallo di 52 settimane | 3,1700 - 5,7500 |
| Volume | |
| Media Volume | 2.914.443 |
| Capitalizzazione | 1,189B |
| Beta (5 anni mensile) | 1,32 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0400 |
| Prossima data utili | 08 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 7,08 |
GlobeNewswireMannKind Corporation Announces Participation at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. H.C. Wainwright 25th Annual Global Investment Conference – Monday, September 11, 2023 at 8:30 am (ET) Morgan Stanley 21st Annual Global Healthcare Conferen
- GlobeNewswire
MannKind Corporation Reports 2023 Second Quarter Financial Results
Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 20232Q 2023 Endocrine Business Unit net revenues of $18M; Afrezza net revenues +27% vs. 2Q 20222Q 2023 Income from operations of $2M; Non-GAAP income from operations of $8M DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended June 30,
- GlobeNewswire
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in one-on-one meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, August 8, 2023 at the Lotte Palace in New York Ci
